LabCorp Q1 2024 Earnings Report
Key Takeaways
Labcorp announced its first quarter 2024 results, with revenue increasing by 4.6% to $3.18 billion. Diluted EPS grew to $2.69, and adjusted EPS reached $3.68. The company updated its full-year guidance, raising the midpoint and narrowing the range of adjusted EPS to $14.45 to $15.35, while free cash flow is expected to remain between $1.00 billion and $1.15 billion.
Revenue increased by 4.6% to $3.18 billion, driven by organic revenue growth and acquisitions.
Diluted EPS increased to $2.69, and adjusted EPS increased to $3.68.
The company updated its full-year adjusted EPS guidance to $14.45 to $15.35.
Labcorp advanced key growth initiatives, including acquisitions and expansion of its test menu.
LabCorp
LabCorp
LabCorp Revenue by Segment
Forward Guidance
Labcorp updated its 2024 full year guidance to reflect its first quarter performance and full year outlook. Adjusted EPS is expected to be in the range of $14.45 to $15.35, and free cash flow from continuing operations is expected to be between $1.00 billion and $1.15 billion.
Positive Outlook
- Revenue growth driven by base business and acquisitions.
- Continued expansion of test menu and innovative solutions.
- Strong position as a partner of choice for health systems and regional/local laboratories.
- Focus on science, technology, and innovation to meet evolving patient needs.
- Commitment to delivering value for customers, shareholders, and employees.
Challenges Ahead
- Potential impact of foreign exchange rate fluctuations.
- Uncertainties related to the completion and timing of the holding company reorganization.
- Impact of global geopolitical events.
- Changes in government regulations, including healthcare reform.
- Adverse weather conditions.
Revenue & Expenses
Visualization of income flow from segment revenue to net income